CandidPharm · Ningbo Candid Pharmaceutical Co., Ltd. · 宁波嘉安药业有限公司
CATEGORY F · CP-ERAV-02Intermediate

(S)-1-(3-(benzyloxy)isoxazol-5-yl)-N,N-dimethylprop-2-en-1-aminium 3-carboxy-2,3-dihydroxypropanoate

(S)-1-[4-(苄基氧基)呋喃-2-基]-N,N-二甲基-2-丙烯-1-胺(2R,3R)-2,3-二羟基琥珀酸盐
CAS Registry No.
1816974-18-1
Related API
Eravacycline dihydrochloride
Molecular Weight
408.4
Product Type
Intermediate

Identification & Structure

Chemical structure of (S)-1-(3-(benzyloxy)isoxazol-5-yl)-N,N-dimethylprop-2-en-1-aminium 3-carboxy-2,3-dihydroxypropanoate
2D Structure

CN(C)[C@@H](C=C)C1=CC(=NO1)OCC2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O

Product CodeCP-ERAV-02
Product TypeIntermediate
CAS Number1816974-18-1
Molecular FormulaC19H24N2O8
Molecular Weight408.4
IUPAC Name(2R,3R)-2,3-dihydroxybutanedioic acid;(1S)-N,N-dimethyl-1-(3-phenylmethoxy-1,2-oxazol-5-yl)prop-2-en-1-amine
SMILESCN(C)[C@@H](C=C)C1=CC(=NO1)OCC2=CC=CC=C2.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O
InChIKeyVFLKFHCVAYVTFA-TZXXFBNGSA-N
PubChem CID138970767
Quality ParametersRequest current specification and available batch documentation

Related API

Listed in our catalog as an intermediate related to Eravacycline dihydrochloride.

Specifications and available documentation are reviewed against your project requirements. Availability and lead time are confirmed for each enquiry, taking current stock and production schedules into account.

Direct Inquiries

Request a Quote & Documents

Tell us the quantity, specification and destination. We will reply by email with pricing, lead time and the documents available.

· We will reply by email
· Mutual NDA available on request

Documents on Request

Request current specification and available batch documentation. We will confirm which TDS, SDS, CoA and analytical materials can be shared for this product.

Patent Notice

Supply is reviewed against the destination, patent status and intended use. Products are not offered where the transaction would infringe valid patents or supplementary protection certificates. Where applicable, regulatory-development activities may fall within the Bolar exemption under Article 10(6) of EU Directive 2001/83/EC, as amended by Directive 2004/27/EC, or 35 U.S.C. § 271(e)(1). These provisions have specific conditions; research use alone does not establish an exemption. Buyers must confirm applicable requirements for their jurisdiction and project before ordering. Commercial supply in protected territories requires an applicable legal basis.